Item 9A. Controls and Procedures
Item 9A. Controls and Procedures.
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, as of December 31, 2025. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2025, our disclosure controls and procedures were effective, at a reasonable assurance level, to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is (a) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and is (b) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. of America.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control-Integrated Framework (2013) . Based on the criteria discussed above and our management’s assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
Except as set forth below, during the quarter ended December 31, 2025, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
On May 20, 2025, we completed the Biolife Merger. We are currently integrating the policies, processes, employees, technology and operations of Biolife. Management does not currently expect a material change to our internal controls over financial reporting as we fully integrate Biolife. Management will continue to evaluate our internal control over financial reporting as we execute acquisition integration activities.
Our independent registered public accountants have also issued an audit report on our internal control over financial reporting. Their report appears below.
92
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the stockholders and the Board of Directors of Merit Medical Systems, Inc.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Merit Medical Systems, Inc. and subsidiaries (the "Company") as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2025, of the Company and our report dated February 24, 2026, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ DELOITTE & TOUCHE LLP
Salt Lake City, Utah
February 24, 2026
93
Table of Contents
Item 9B. Other Information.
None of our directors or officers informed us of the adop tion or termi nation of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, during the three-month period ended December 31, 2025.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
PART III
Items 10, 11, 12, 13 and 14.
The information required by these items is incorporated by reference to our definitive proxy statement relating to our 2026 Annual Meeting of Shareholders. We currently anticipate that our definitive proxy statement will be filed with the SEC not later than 120 days after December 31, 2025, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended.
Merit has adopted an insider trading policy which governs the purchase, sale, and/or any other dispositions of our securities by our directors, officers and employees and is designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to Merit. A copy of our insider trading policy is filed with this report as Exhibit 19.1.
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(a) Documents filed as part of this Report:
(1) Financial Statements . The following consolidated financial statements and the notes thereto, and the Reports of Independent Registered Public Accounting Firm are incorporated by reference as provided in Item 8 and Item 9A of this report:
Report of Independent Registered Public Accounting Firm (PCAOB ID 34 ) — Internal Control
Report of Independent Registered Public Accounting Firm — Financial Statements
Consolidated Balance Sheets as of December 31, 2025 and 2024
Consolidated Statements of Income for the Years Ended December 31, 2025, 2024 and 2023
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2025, 2024 and 2023
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025, 2024 and 2023
Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024 and 2023
Notes to Consolidated Financial Statements
94
Table of Contents
(2) Financial Statement Schedules.
Schedule II - Valuation and qualifying accounts
Years Ended December 31, 2025, 2024 and 2023
(In thousands)
Balance at
Additions Charged to
Balance at
Allowance for Credit Losses:
Beginning of Year
Costs and Expenses (a)
Deduction (b)
End of Year
2023
$
( 8,423 )
$
( 1,772 )
$
1,172
$
( 9,023 )
2024
$
( 9,023 )
$
( 1,425 )
$
719
$
( 9,729 )
2025
$
( 9,729 )
$
( 2,964 )
$
2,557
$
( 10,136 )
(a) We record a provision for credit losses based upon historical bad debt experience, current economic conditions, expectations of future economic conditions, and management’s evaluation of our ability to collect individual outstanding balances.
(b) When an individual customer balance becomes impaired and is deemed uncollectible, a deduction is made against the allowance for credit losses.
Years Ended December 31, 2025, 2024 and 2023
(In thousands)
Balance at
Additions Charged to
Balance at
Tax Valuation Allowance:
Beginning of Year
Costs and Expenses (a)
Deduction
End of Year
2023
$
( 13,527 )
$
( 213 )
$
-
$
( 13,740 )
2024
$
( 13,740 )
$
( 403 )
$
-
$
( 14,143 )
2025
$
( 14,143 )
$
22
$
-
$
( 14,121 )
(a) We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.
(b) Exhibits:
The following exhibits required by Item 601 of Regulation S-K are filed herewith or have been filed previously with the SEC as indicated below:
Index to Exhibits
Incorporated by Reference
Exhibit No.
Exhibit Description
Form
Exhibit
Filing Date
2.1
Asset Purchase Agreement, dated July 1, 2024, between Merit Medical Systems, Inc. and Endogastric Solutions, Inc.*
10-Q
2.1
August 1, 2024
2.2
Asset Purchase Agreement, dated September 16, 2024, between Merit Medical Systems, Inc. and Cook Medical Holdings LLC.*#
10-Q
2.1
October 30, 2024
2.3
Agreement and Plan of Merger among Merit Medical Systems, Inc., Biolife Transaction Sub, LLC, Biolife, L.L.C., and Shareholder Representative Services LLC, dated as of May 16, 2025.*
10-Q
2.1
July 30, 2025
3.1
Second Amended and Restated Articles of Incorporation.*
10-Q
3.1
August 9, 2018
95
Table of Contents
3.2
F ourth Amended and Restated Bylaws.*
8-K
3.1
May 21, 2024
4.1
Specimen Certificate of the Common Stock.*
S-18
10
October 19, 1989
4.2
Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 .
—
—
—
10.1
Lease Agreement, dated as of June 8, 1993, between QRS 11-20 (UT), Inc. and Merit Medical Systems, Inc. for office and manufacturing facility.*
10-K
10.4
March 31, 1995
10.2
A mended and Restated Deferred Compensation Plan, dated January 1, 2004.*†
10-K
10.12
March 15, 2004
10.3
Merit Medical Systems, Inc. Amended and Restated Deferred Compensation Plan, effective January 1, 2008.*†
8-K
10.1
December 18, 2008
10.4
Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, made and adopted effective May 31, 2009.*†
8-K
10.1
January 7, 2010
10.5
First Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, effective September 19, 2010.*†
S-8
4.9
August 11, 2015
10.6
Second Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated November 29, 2010. *†
S-8
4.10
August 11, 2015
10.7
Third Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, effective October 1, 2010.*†
S-8
4.11
August 11, 2015
10.8
Fourth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated December 31, 2011.*†
S-8
4.12
August 11, 2015
10.9
Fifth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated December 28, 2012.*†
S-8
4.13
August 11, 2015
10.10
Sixth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated December 31, 2013.*†
S-8
4.14
August 11, 2015
10.11
Seventh Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated June 10, 2014.*†
10-Q
10.1
August 11, 2014
10.12
Eighth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated December 29, 2014.*†
S-8
4.16
August 11, 2015
96
Table of Contents
10.13
Employment Agreement, dated May 26, 2016 between Merit Medical Systems, Inc. and Brian G. Lloyd.*†
10-Q
10.3
August 8, 2016
10.14
Merit Medical Systems, Inc., Restatement of the 1996 Employee Stock Purchase Plan dated July 1, 2000.*†
10-K
10.23
March 1, 2017
10.15
First Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated April 1, 2001.*†
10-K
10.24
March 1, 2017
10.16
Second Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated January 1, 2006.*†
10-K
10.25
March 1, 2017
10.17
Third Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated April 7, 2006.*†
10-K
10.26
March 1, 2017
10.18
Fourth Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated February 13, 2015.*†
10-K
10.27
March 1, 2017
10.19
Fifth Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated April 15, 2021.*†
10-Q
10.3
August 6, 2021
10.20
First Amendment to Employment Agreement, dated December 11, 2017, between Merit Medical Systems, Inc. and Brian G. Lloyd.*†
8-K
10.3
December 15, 2017
10.21
First Amendment to Lease Agreement dated May 22, 2017 for office and manufacturing facility.*
10-K
10.29
March 1, 2018
10.22
Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan effective May 24, 2018.*†
S-8
4.2
June 4, 2018
10.23
First Amendment to the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan effective December 14, 2018.*†
10-K
10.32
March 1, 2019
10.24
Second Amendment to the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan effective April 15, 2021.*†
10-Q
10.2
August 6, 2021
10.25
Employment Agreement made and entered into between Merit Medical Systems, Inc. and Raul Parra as of the 1st day of August, 2018.*†
10-Q
10.3
August 9, 2018
10.26
Merit Medical Systems, Inc. 2019 Executive Bonus Plan, dated January 1, 2019.*†
10-Q
10.2
May 3, 2019
10.27
Ninth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated August 1, 2016.*†
10-Q
10.1
August 9, 2019
10.28
Tenth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated January 1, 2017.*†
10-Q
10.2
August 9, 2019
97
Table of Contents
10.29
Eleventh Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated January 1, 2019.*†
10-Q
10.3
August 9, 2019
10.30
Twelfth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, dated June 1, 2018.*†
10-Q
10.4
August 9, 2019
10.31
Thirteenth Amendment to the Second Restatement of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, effective January 1, 2019.*†
10-K
10.48
March 2, 2020
10.32
First Amendment to the Merit Medical Systems, Inc. 2019 Executive Bonus Plan, effective June 22, 2020.*†
8-K
10.3
June 26, 2020
10.33
Settlement Agreement, dated October 13, 2020, among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (“OIG-HHS”) of the Department of Health and Human Services (“HHS”), and the Defense Health Agency (“DHA”), acting on behalf of the TRICARE Program (collectively, the “United States”); Merit Medical Systems, Inc.; and Charles J. Wolf, M.D. (“Relator”), through their authorized representatives.*
8-K
10.1
October 16, 2020
10.34
Form of Indemnification Agreement, dated October 24, 2020, between Merit Medical Systems, Inc. and each of the following individuals: F. Ann Millner, Ed. D., Lynne N. Ward, and Thomas J. Gunderson.*†
10-K
10.49
March 1, 2021
10.35
Form of Indemnification Agreement, dated October 24, 2020, between Merit Medical Systems, Inc. and each of the following individuals: Lonny J. Carpenter, and David K. Floyd.*†
10-K
10.50
March 1, 2021
10.36
Form of Indemnification Agreement between Merit Medical Systems, Inc. and each executive officer.*†
10-K
10.51
March 1, 2021
10.37
Indemnification Agreement, dated as of June 17, 2021, between Merit Medical Systems, Inc. and Stephen C. Evans.*†
10-Q
10.1
October 28, 2022
10.38
Form of Indemnification Agreement, dated as of May 19, 2022, between Merit Medical Systems, Inc. and each of Laura Kaiser and Michael McDonnell.*†
10-Q
10.2
October 28, 2022
10.39
Employment Agreement between Merit Medical Systems, Inc. and Michel J. Voigt, dated December 11, 2020.*†
10-K
10.53
March 1, 2021
10.40
Employment Agreement between Merit Medical Systems, Inc. and Neil Peterson, dated May 19, 2022.*†
10-K
10.51
February 24, 2023
10.41
Second Amendment to Lease Agreement dated March 10, 2022, between MM (UT) QRS 11-59, Inc. and Merit Medical Systems, Inc. for office and manufacturing facility.*
10-K
10.61
February 24, 2023
98
Table of Contents
10.42
Deferred Compensation Plan for Non-Employee Directors, effective as of July 22, 2022.*†
10-Q
10.1
August 5, 2022
10.43
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2023, between Merit Medical Systems, Inc. and Fred Lampropoulos.*†
10-Q
10.1
April 28, 2023
10.44
Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2023, between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, Brian G. Lloyd, and Michel J. Voigt.*†
10-Q
10.2
April 28, 2023
10.45
Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, between Merit Medical Systems, Inc. and Fred Lampropoulos.*†
10-Q
10.3
April 30, 2024
10.46
Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, and Brian Lloyd.*†
10-Q
10.4
April 30, 2024
10.47
Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, between Merit Medical Systems, Inc. and Mike Voigt.*†
10-Q
10.5
April 30, 2024
10.48
Restricted Stock Unit Award Agreement, dated March 9, 2024, between Merit Medical Systems, Inc. and Fred Lampropoulos.*†
10-Q
10.6
April 30, 2024
10.49
Form of Restricted Stock Unit Award Agreement, dated March 4, 2024, between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, and Brian Lloyd.*†
10-Q
10.7
April 30, 2024
10.50
Restricted Stock Unit Award Agreement, dated March 8, 2024, between Merit Medical Systems, Inc. and Mike Voigt.*†
10-Q
10.8
April 30, 2024
10.51
Indemnification Agreement, dated May 15, 2024, between Merit Medical Systems, Inc. and Silvia M. Perez.*
8-K
10.1
May 21, 2024
10.52
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Fred Lampropoulos.*†
10-Q
10.3
April 24, 2025
10.53
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Raul Parra.*†
10-Q
10.4
April 24, 2025
10.54
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Brian Lloyd.*†
10-Q
10.5
April 24, 2025
10.55
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Neil Peterson.*†
10-Q
10.6
April 24, 2025
99
Table of Contents
10.56
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Mike Voigt.*†
10-Q
10.7
April 24, 2025
10.57
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Fred Lampropoulos.*†
10-Q
10.8
April 24, 2025
10.58
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Raul Parra.*†
10-Q
10.9
April 24, 2025
10.59
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Brian Lloyd.*†
10-Q
10.10
April 24, 2025
10.60
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Neil Peterson.*†
10-Q
10.11
April 24, 2025
10.61
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Mike Voigt.*†
10-Q
10.12
April 24, 2025
10.62
Form of Restricted Stock Unit Award Agreement, dated May 15, 2025, between Merit Medical Systems, Inc. and each of the following individuals: Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, Thomas J. Gunderson, Laura S. Kaiser, Michael R. McDonnell, F. Ann Millner, Silvia M. Perez and Lynne N. Ward.*†
10-Q
10.1
July 30, 2025
10.63
Performance Stock Unit Award Agreement (Three Year Performance Period), dated October 3, 2025, between Merit Medical Systems, Inc. and Martha G. Aronson.*†
10-Q
10.2
October 30, 2025
10.64
Restricted Stock Unit Award Agreement, dated October 3, 2025, between Merit Medical Systems, Inc. and Martha G. Aronson.*†
10-Q
10.3
October 30, 2025
10.65
Chief Executive Officer Employment Agreement, dated October 3, 2025, between Merit Medical Systems, Inc. and Martha G. Aronson.*†
10-Q
10.1
October 30, 2025
10.66
Indemnification Agreement, dated October 3, 2025, between Merit Medical Systems, Inc. and Martha G. Aronson.†
—
—
—
10.67
CEO Transition Agreement, dated October 3, 2025, between Merit Medical Systems, Inc. and Fred P. Lampropoulos.*†
10-Q
10.4
October 30, 2025
10.68
Consulting Agreement, dated January 7, 2026, between Merit Medical Systems, Inc. and Fred P. Lampropoulos.†#
—
—
—
10.69
Employment Agreement, dated September 1, 2025, between Merit Medical Systems, Inc. and Christian Adam Smith.*†
10-Q
10.5
October 30, 2025
10.70
Indemnification Agreement, dated September 1, 2025, between Merit Medical Systems, Inc. and Christian Adam Smith.*†
10-Q
10.6
October 30, 2025
100
Table of Contents
10.71
Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, between Merit Medical Systems, Inc. and Christian Adam Smith.†
—
—
—
10.72
Restricted Stock Unit Award Agreement, dated February 28, 2025, between Merit Medical Systems, Inc. and Christian Adam Smith.†
—
—
—
10.73
Restricted Stock Unit Award Agreement, dated May 22, 2025, between Merit Medical Systems, Inc. and Christian Adam Smith.†
—
—
—
10.74
Fourth Amended and Restated Credit Agreement, dated June 6, 2023, among Merit Medical Systems, Inc. as Borrower and the Lenders referred to therein, as Lenders, and Wells Fargo Bank, National Association, as Administrative Agent, and Wells Fargo Securities, LLC, BOFA Securities, Inc., HSBC Bank USA, National Association, U.S. Bank National Association and Truist Securities, Inc., as Joint Lead Arrangers and Joint Bookrunners, and Bank of America, N.A., HSBC Bank USA, National Association, U.S Bank National Association and Truist Bank as Co-Syndication Agents and TD Bank, N.A., as Documentation Agent.*
10-Q
10.2
July 28, 2023
10.75
Amended and Restated Employment Agreement, dated June 8, 2023, between Merit Medical Systems, Inc. and Fred P. Lampropoulos.*
8-K
99.3
June 8, 2023
10.76
Indenture, dated as of December 8, 2023, among Merit Medical Systems, Inc., and U.S. Bank Trust Company, National Association, as trustee.*
8-K
4.1
December 8, 2023
10.77
Form of 3.00% Convertible Senior Note due 2029.*
8-K
4.2
December 8, 2023
10.78
Form of Capped Call Confirmation. *
8-K
10.1
December 8, 2023
10.79
First Amendment to the Fourth Amended and Restated Credit Agreement dated December 5, 2023, among certain subsidiaries of Merit Medical Systems, Inc., Wells Fargo Bank, National Association, as administrative agent for Lenders, Bank of America, N.A., HSBC Bank USA, National Association, U.S. Bank National Association, Truist Bank, TD Bank, N.A., Huntington National Bank, and Regions Bank.
10-K
10.68
February 28, 2024
10.80
Rule 10b5-1 Trading Plan, dated August 7, 2023, between F. Ann Millner and E*TRADE Securities LLC.*
10-K
10.69
February 28, 2024
10.81
Rule 10b5-1 Trading Plan, dated March 11, 2024, between Neil W. Peterson and Morgan Stanley Smith Barney LLC.*
10-Q
10.1
April 30, 2024
10.82
Rule 10b5-1 Trading Plan, dated March 15, 2024, between Raul Parra and Morgan Stanley Smith Barney LLC.*
10-Q
10.2
April 30, 2024
10.83
Rule 10b5-1 Trading Plan, dated November 6, 2024, between Neil W. Peterson and Morgan Stanley Smith Barney LLC.*
10-K
10.78
February 25, 2025
101
Table of Contents
10.84
Rule 10b5-1 Trading Plan, dated February 28, 2025, between David K. Floyd and Charles Schwab & Co., Inc.*
10-Q
10.1
April 24, 2025
10.85
Rule 10b5-1 Trading Plan, dated February 28, 2025, between Michael R. McDonnell and Morgan Stanley Smith Barney LLC.*
10-Q
10.2
April 24, 2025
19.1
Corporate Policy on Insider Trading (revised May 15, 2025)*
10-Q
19.1
July 30, 2025
21
Subsidiaries of Merit Medical Systems, Inc.
—
—
—
23.1
Consent of Independent Registered Public Accounting Firm .
—
—
—
31.1
Certification of Chief Executive Officer .
—
—
—
31.2
Certification of Chief Financial Officer .
—
—
—
32.1
Certification of Chief Executive Officer .
—
—
—
32.2
Certification of Chief Financial Officer .
—
—
—
97
Policy Relating to the Recovery of Erroneously Awarded Compensation. *†
10-K
97
February 28, 2024
101
The following materials from the Merit Medical Systems, Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Statements of Income, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows, (v) Consolidated Statements of Equity, and (vi) Notes to Consolidated Financial Statements.
—
—
—
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).
—
—
—
*
These exhibits are incorporated herein by reference.
†
Indicates management contract or compensatory plan or arrangement.
#
Portions of this exhibit have been omitted.
(c) Schedules:
None
Item 16. Form 10-K Summary.
None.
102
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on February 24, 2026.
MERIT MEDICAL SYSTEMS, INC.
By:
/s/ MARTHA G. ARONSON
Martha G. Aronson, President and
Chief Executive Officer
ADDITIONAL SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on form 10-K has been signed below by the following persons in the capacities indicated on February 24, 2026.
Signature
Capacity in Which Signed
/s/ MARTHA G. ARONSON
President, Chief Executive Officer and Director
Martha G. Aronson
(Principal executive officer)
/s/ RAUL PARRA
Chief Financial Officer and Treasurer
Raul Parra
(Principal financial and accounting officer)
/s/ F. ANN MILLNER
Director
F. Ann Millner
/s/ LONNY J. CARPENTER
Director
Lonny J. Carpenter
/s/ STEPHEN C. EVANS
Director
Stephen C. Evans
/s/ DAVID K. FLOYD
Director
David K. Floyd
/s/ THOMAS J. GUNDERSON
Director
Thomas J. Gunderson
/s/ LAURA S. KAISER
Director
Laura S. Kaiser
/s/ MICHAEL R. MCDONNELL
Director
Michael R. McDonnell
/s/ SILVIA M. PEREZ
Director
Silvia M. Perez
/s/ LYNNE N. WARD
Director
Lynne N. Ward
103